Index NDX, S&P 500
P/E 180.20
EPS (ttm) 0.69
Insider Own 0.10%
Shs Outstand 386.70M
Perf Week 1.44%
Market Cap 47.02B
Forward P/E 83.06
EPS next Y 1.50
Insider Trans -40.32%
Shs Float 384.65M
Perf Month 1.44%
Income 292.50M
PEG 9.39
EPS next Q 0.23
Inst Own 98.80%
Short Float / Ratio 3.76% / 6.37
Perf Quarter 15.38%
Sales 3.02B
P/S 15.56
EPS this Y 57.80%
Inst Trans -0.36%
Short Interest 14.46M
Perf Half Y 5.45%
Book/sh 5.77
P/B 21.55
EPS next Y 37.47%
ROA 5.60%
Target Price 140.70
Perf Year 62.59%
Cash/sh 6.79
P/C 18.32
EPS next 5Y 19.20%
ROE 13.90%
52W Range 67.11 - 126.59
Perf YTD 9.80%
Dividend -
P/FCF 113.04
EPS past 5Y 37.80%
ROI 8.20%
52W High -1.78%
Beta 1.15
Dividend % -
Quick Ratio 1.80
Sales past 5Y 32.30%
Gross Margin 64.90%
52W Low 85.28%
ATR 3.71
Employees 7500
Current Ratio 2.00
Sales Q/Q 17.90%
Oper. Margin 13.10%
RSI (14) 58.63
Volatility 3.69% 3.07%
Optionable Yes
Debt/Eq 0.91
EPS Q/Q -48.80%
Profit Margin 9.70%
Rel Volume 0.93
Prev Close 121.13
Shortable Yes
LT Debt/Eq 0.56
Earnings Apr 27 AMC
Payout 0.00%
Avg Volume 2.27M
Price 124.34
Recom 1.50
SMA20 4.45%
SMA50 4.74%
SMA200 13.86%
Volume 2,121,056
Change 2.65%
Date
Action
Analyst
Rating Change
Price Target Change
May-30-23 Resumed
Morgan Stanley
Equal-Weight
$131
Apr-17-23 Upgrade
Raymond James
Outperform → Strong Buy
$127 → $138
Mar-29-23 Initiated
UBS
Buy
$142
Jan-26-23 Initiated
Wolfe Research
Outperform
$121
Oct-18-22 Initiated
Barclays
Equal Weight
$103
Oct-12-22 Initiated
Jefferies
Buy
$125
Jul-15-22 Initiated
Bernstein
Outperform
$105
Mar-02-22 Resumed
BofA Securities
Buy
$500
Feb-03-22 Upgrade
BTIG Research
Neutral → Buy
$535
Jan-19-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$575
Jan-07-22 Upgrade
Guggenheim
Neutral → Buy
$580
Oct-18-21 Downgrade
Guggenheim
Buy → Neutral
Jul-21-21 Resumed
Cowen
Outperform
$540 → $525
May-28-21 Upgrade
Wells Fargo
Underweight → Equal Weight
$380
May-25-21 Initiated
Barclays
Overweight
$500
Apr-15-21 Initiated
Atlantic Equities
Overweight
$438
Jan-06-21 Upgrade
UBS
Neutral → Buy
$410 → $445
Oct-02-20 Downgrade
Wells Fargo
Equal Weight → Underweight
$420 → $350
May-27-20 Reiterated
Piper Sandler
Overweight
$375 → $450
May-14-20 Initiated
Wells Fargo
Equal Weight
$420
Show Previous Ratings
Jun-09-23 11:30AM
Jun-08-23 04:13PM
08:30AM
Jun-06-23 07:18AM
06:29AM (Investor's Business Daily)
05:30AM
Loading…
05:30AM
Jun-05-23 08:55PM (Investor's Business Daily)
Jun-04-23 10:59AM
09:28AM (Investor's Business Daily)
Jun-03-23 11:52AM (Investor's Business Daily)
08:00AM (Investor's Business Daily)
07:45AM
Jun-01-23 10:04AM
08:30AM
May-31-23 09:37AM
05:06AM
Loading…
05:06AM
May-25-23 10:14AM
10:07AM
May-24-23 09:00AM
May-23-23 09:55AM
May-22-23 05:43PM
May-17-23 08:45AM
May-16-23 07:54AM
May-15-23 08:50AM
May-13-23 08:00AM (Investor's Business Daily)
May-11-23 01:25PM (Investor's Business Daily)
May-10-23 06:30PM
08:07AM
May-04-23 12:40PM
May-03-23 07:00AM
04:00AM
Loading…
04:00AM
May-02-23 07:00AM
05:14AM
Apr-29-23 08:58AM (Investor's Business Daily)
Apr-28-23 03:33PM
12:11PM
11:24AM
09:56AM
09:28AM (Investor's Business Daily)
Apr-27-23 05:25PM
04:27PM (Investor's Business Daily)
04:03PM
10:23AM
06:00AM
Apr-26-23 08:00PM
08:00PM
10:52AM
Apr-25-23 10:20AM
Apr-24-23 06:35AM
Apr-20-23 08:10AM
Apr-19-23 09:40AM
Apr-17-23 04:53PM (Investor's Business Daily)
12:23PM (Investor's Business Daily)
09:45AM
08:00AM
Apr-13-23 04:28PM (Investor's Business Daily)
09:45AM
07:25AM
Apr-08-23 09:45AM
Apr-06-23 07:45AM
05:30AM
03:59AM
Apr-05-23 09:08AM
09:00AM
Apr-02-23 03:16PM
Mar-31-23 06:15PM
08:45AM
Mar-29-23 07:45AM
Mar-25-23 05:41AM
Mar-24-23 12:10PM (Investor's Business Daily)
11:59AM
06:59AM
Mar-23-23 09:53AM
Mar-21-23 06:15PM
06:00AM
Mar-20-23 09:00AM
02:15AM
Mar-18-23 06:29PM
Mar-16-23 11:14AM (Investor's Business Daily)
Mar-15-23 06:15PM
Mar-13-23 07:30AM
Mar-09-23 06:15PM
09:53AM
08:00AM
Mar-08-23 10:19PM
Mar-07-23 04:59AM
Mar-06-23 04:04PM (Investor's Business Daily) -7.87%
10:05AM
Mar-03-23 06:15PM
02:38PM
08:20AM
Mar-02-23 04:04PM (Investor's Business Daily) +9.46%
05:05AM
Feb-28-23 04:56PM
05:52AM
05:00AM
Feb-24-23 09:45AM
09:37AM
Feb-23-23 09:00AM
Feb-22-23 04:04PM (Investor's Business Daily)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pacelli Steven Robert EVP Managing Director Dexcom V May 23 Sale 118.65 412 48,884 132,274 May 23 07:13 PM Sylvain Jereme M EVP Chief Financial Officer May 22 Sale 117.58 2,400 282,192 74,711 May 23 07:12 PM Stern Sadie EVP Chief Human Resources Offi May 09 Sale 120.19 393 47,235 82,859 May 09 06:24 PM Pacelli Steven Robert EVP Managing Director Dexcom V Apr 27 Sale 126.00 5,031 633,906 132,686 Apr 27 06:38 PM Pacelli Steven Robert EVP Managing Director Dexcom V Apr 24 Sale 124.68 412 51,368 137,717 Apr 26 04:36 PM Leach Jacob Steven EVP Chief Technology Officer Apr 20 Sale 125.00 30,764 3,845,500 259,613 Apr 20 06:39 PM Regan Barry J. EVP Operations Apr 20 Sale 124.50 2,214 275,643 68,258 Apr 20 06:39 PM Selvaraj Shelly Ramasamy SVP Chief Information Officer Apr 20 Sale 125.00 2,007 250,875 52,505 Apr 20 06:39 PM Flynn Paul R EVP Global Revenue Apr 17 Sale 120.00 2,781 333,720 52,112 Apr 18 04:36 PM Stern Sadie EVP Chief Human Resources Offi Apr 10 Sale 112.35 393 44,154 83,252 Apr 11 04:02 PM SAYER KEVIN R President CEO and Chairman of Apr 03 Sale 114.46 20,812 2,382,069 327,457 Apr 05 04:56 PM Brown Michael Jon EVP Chief Legal Officer Apr 03 Sale 114.48 3,612 413,490 61,870 Apr 05 04:56 PM Pacelli Steven Robert EVP Managing Director Dexcom V Mar 23 Sale 116.40 5,442 633,449 138,129 Mar 27 05:08 PM Dolan Matthew Vincent SVP Corporate Strategy-Develop Mar 16 Sale 115.00 2,303 264,845 33,569 Mar 17 04:14 PM Stern Sadie EVP Chief Human Resources Offi Mar 14 Sale 111.86 393 43,961 83,645 Mar 15 04:03 PM Dolan Matthew Vincent SVP Corporate Strategy-Develop Mar 13 Sale 106.27 6,229 661,956 35,872 Mar 14 04:46 PM Flynn Paul R EVP Global Revenue Mar 13 Sale 106.27 2,782 295,643 54,893 Mar 14 04:46 PM Regan Barry J. EVP Operations Mar 13 Sale 106.27 2,010 213,603 70,472 Mar 14 04:46 PM Leach Jacob Steven EVP Chief Technology Officer Mar 06 Sale 114.74 18,144 2,081,822 281,089 Mar 06 08:05 PM Dolan Matthew Vincent SVP Corporate Strategy-Develop Mar 06 Sale 114.40 226 25,854 26,536 Mar 06 08:04 PM SAYER KEVIN R President CEO and Chairman of Mar 01 Sale 109.94 38,464 4,228,611 331,337 Mar 02 05:16 PM Pacelli Steven Robert EVP Managing Director Dexcom V Feb 23 Sale 111.64 412 45,996 136,464 Feb 23 06:34 PM Sylvain Jereme M EVP Chief Financial Officer Feb 22 Sale 114.54 2,400 274,896 64,837 Feb 22 06:08 PM SAYER KEVIN R President CEO and Chairman of Jan 30 Sale 106.15 56,844 6,034,123 369,801 Jan 31 04:07 PM Regan Barry J. EVP Operations Jan 30 Sale 106.12 2,213 234,844 59,386 Jan 31 04:07 PM Pacelli Steven Robert EVP Managing Director Dexcom V Jan 23 Sale 107.86 412 44,438 136,876 Jan 24 04:16 PM SAYER KEVIN R President CEO and Chairman of Jan 20 Sale 105.75 45,607 4,822,872 426,645 Jan 24 04:17 PM Pacelli Steven Robert EVP Managing Director Dexcom V Dec 23 Sale 112.57 412 46,379 137,288 Dec 27 04:29 PM Flynn Paul R EVP Global Revenue Dec 08 Sale 123.50 8,988 1,110,018 55,744 Dec 08 06:07 PM Sylvain Jereme M EVP Chief Financial Officer Nov 21 Sale 112.62 2,400 270,288 67,237 Nov 22 06:25 PM Dolan Matthew Vincent SVP Corporate Strategy-Develop Sep 01 Sale 81.63 5 408 26,536 Sep 06 09:33 AM Pacelli Steven Robert EVP Managing Director Dexcom V Aug 23 Sale 84.21 1,000 84,210 137,700 Aug 24 05:25 PM Pacelli Steven Robert EVP Managing Director Dexcom V Jul 25 Sale 83.07 1,000 83,070 138,700 Jul 25 06:00 PM Pacelli Steven Robert EVP Managing Director Dexcom V Jun 23 Sale 72.55 1,000 72,550 139,700 Jun 27 04:46 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite